Here I am , sitting waiting for some answers, mco is over 6o % of portfolio, if we have a company with no B@#$S, My investment and respect for current management is disappointingly low
MSB Mesoblast resubmits US FDA application for approval of Ryoncil in children with graft vs host disease; shares dip -4%